Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05022693 · ClinicalTrials.gov registry record · Phase 1
PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis
A Phase 1 study of NASH - Nonalcoholic Steatohepatitis, sponsored by 89bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT05022693 is a Phase 1 study of NASH - Nonalcoholic Steatohepatitis that has completed, run by 89bio. The registered enrollment target is 8 participants, below the 269-participant average among 27 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05022693, a Phase 1 study of NASH - Nonalcoholic Steatohepatitis, has completed, sponsored by 89bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, single-dose study to evaluate the PK profile of the liquid SC formulation of BIO89-100 in approximately 8 male and female subjects with NASH with compensated cirrhosis.
Conditions Studied
Interventions
- DRUG BIO89-100
Study Locations (1)
Arizona
- 89bio Clinical Study Site - Chandler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-08-16 |
| Est. Completion | 2021-12-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05022693
The ClinicalTrials.gov registry entry for NCT05022693 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 269-participant average among 27 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (97% lower). The listed sponsor is 89bio, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with NASH - Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 1 intervention - of which BIO89-100 is the first listed.
NCT05022693 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT05022693 about?
NCT05022693 is a clinical study titled "PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis". This is an open-label, single-dose study to evaluate the PK profile of the liquid SC formulation of BIO89-100 in approximately 8 male and female subjects with NASH with compensated cirrhosis.
What is the current status of trial NCT05022693?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-08-16. Estimated completion is 2021-12-21.
What conditions does trial NCT05022693 study?
This clinical trial studies the following conditions: NASH - Nonalcoholic Steatohepatitis.
What interventions are being tested in trial NCT05022693?
The interventions under investigation include: BIO89-100 (DRUG).
Who is sponsoring clinical trial NCT05022693?
This trial is sponsored by 89bio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05022693 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NASH - Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects
COMPLETED · Phase 1
-
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
COMPLETED · Phase 1
-
Study of Gemcabene in Adults With FPLD
COMPLETED · Phase 1
-
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
RECRUITING
-
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
RECRUITING · NA
-
Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.